Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
\n\nSource: Pocket Manual of Therapy \(Bartoccioni et al.\) / FDA and EMA Nephrology Updates To view or add a comment, sign in 7,166 followers
7.4.4 Next-generation agonists The development of dual GLP-1/GIP receptor agonists (e.g., tirzepatide) and novel blood-brain barrier-penetrant formulations may offer superior neuroprotective efficacy by more potently engaging central receptors or providing a broader spectrum of action (Ghaleb et al., 2025)
Saha P, Kathuria H, Pandey MM
While BMI is a valuable tool, measures of central adiposity, such as waist circumference, provide additional insight into cardiometabolic risks
)
US$ 24.60
US$ 28.84
US$ 20.01
US$ 23.64
